Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on Sept 2nd with a press release - check it for news.
AI Summary
Innate Pharma S.A. filed a Form 6-K on September 2, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to investors, likely containing important business or financial news.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily announces a press release without disclosing new material financial or operational information.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- September 2, 2025 (date) — Filing date and press release date
FAQ
What is the subject of the press release filed as Exhibit 99.1?
The filing does not specify the subject of the press release dated September 2, 2025, only that it is included as Exhibit 99.1.
What is Innate Pharma's principal executive office address?
Innate Pharma's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma file annual reports under Form 20-F or 40-F?
Innate Pharma indicates it files annual reports under Form 20-F.
What is the Commission File Number for Innate Pharma?
Innate Pharma's Commission File Number is 001-39084.
What is the SIC code for Innate Pharma?
Innate Pharma's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 158 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-09-02 08:52:09
Filing Documents
- a6k-iphx250902.htm (6-K) — 8KB
- exhibit991-250902.htm (EX-99.1) — 14KB
- 0001598599-25-000070.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 2, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive officer